comparemela.com

Latest Breaking News On - அமரின் பார்மா இன்க் - Page 1 : comparemela.com

PM360 Magazine Announces Winners of 2021 Trailblazer Awards

PM360 Magazine Announces Winners of 2021 Trailblazer Awards
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

PM360 Magazine Announces Winners of 2021 Trailblazer Awards

PM360 Magazine Announces Winners of 2021 Trailblazer Awards
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Hikma Should Face Amarin s Patent Suit, Magistrate Says

Law360 ADVERTISEMENT Hikma Should Face Amarin s Patent Suit, Magistrate Says Law360 (August 3, 2021, 8:54 PM EDT) Hikma Pharmaceuticals should not be able to dodge a lawsuit claiming it encouraged doctors to prescribe its generic version of the heart drug Vascepa for uses covered by a series of Amarin patents, a Delaware federal magistrate judge says. Magistrate Judge Jennifer L. Hall on Tuesday issued a report and recommendation in a lawsuit filed by Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Ltd. and Mochida Pharmaceutical Co. Ltd. alleging that Hikma induced infringement of three patents. Specifically, Amarin alleged in the so-called skinny label case that Hikma induced doctors to infringe the patents by instructing them to use the Hikma generic.

Why would millions at risk of heart attack or stroke be prescribed medications not proven to reduce cardiovascular risk on top of statins?

(BPT) - As the world looks with hope to the light at the end of the COVID-19 tunnel, there lies another ongoing health crisis that, according to the American Heart Association (AHA), kills more Americans than anything else: heart disease. In the last year, heart disease claimed more than 690,000 lives in the U.S., which is staggeringly more than the reported 345,000 lives lost to COVID-19, according to data from the Centers for Disease Control and Prevention. With the prevalence of this disease and the large amount of clinical data surrounding the management of CV risk factors, one would assume that the approaches used to reduce the risk of a CV event, such as a heart attack or stroke, would be standard practice. However, the overwhelming amount of information and data out there can actually make it hard to assess risk and treatment options, and it can be confusing for physicians, patients and caregivers to figure out what is best — especially when data changes old ways of th

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.